Nutriband Advances with FDA on Fentanyl Patch
I'm PortAI, I can summarize articles.
Nutriband Inc. has successfully met with the US FDA regarding its AVERSA™ FENTANYL patch, aimed at addressing fentanyl patch abuse. The meeting provided crucial feedback for their development program as they prepare for an IND filing. Projected US sales could reach $80 million to $200 million annually. Analyst ratings for NTRB stock are mixed, with a Buy rating and a $15.00 price target, while Spark's AI Analyst rates it as Neutral due to financial challenges. Nutriband focuses on developing transdermal products to prevent drug abuse.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments